We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 37

Moneytree report shows increased life sciences investments in Q1 2011

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall

Pharma and biotech stocks rise, M&A and IPO values strong, licensing deals

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 26 2013

Market analysts commenting on the dramatic rise in the Nasdaq Biotech Index (up 27) and the Dow Jones US Pharma Index (up 21) in the first half of

Pharma merger activity attributed to “patent cliff”

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 18 2010

Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies

Israeli biotechnology startups seek partnerships in Ohio

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • December 16 2010

Israeli biotechnology companies are reportedly heading to Ohio because of state incentives and a venture capital fund focused on investing in Israel

Barbados launches biotech initiative designed to shorten R&D process

  • Shook Hardy & Bacon LLP
  • -
  • Barbados
  • -
  • December 16 2010

The Barbados government has recently launched two initiatives to attract biotech companies to the island nation

Quebec establishes new venture capital fund to invest in biotech research

  • Shook Hardy & Bacon LLP
  • -
  • Canada
  • -
  • February 24 2011

Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research

Synageva announces $25 million for rare disease product development

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 7 2011

Synageva BioPharma Corp. has announced an additional $25 million in private equity financing to support therapeutic product development

Biotech companies struggling in public markets

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 7 2011

While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand

Fewer small biotech companies go public

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 10 2011

Smaller biotechnology companies maneuvering through drug-development regulations are reportedly focusing their efforts on licensing products in development or selling their businesses to large pharmaceutical companies rather than pursuing an initial public offering (IPO

Agilent Technologies acquires BIOCIUS Life Sciences

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 10 2011

California-based Agilent Technologies has announced the acquisition of BIOCIUS Life Sciences, a Massachusetts-based company that developed a spectrometry device, enabling "researchers to gain a fuller understanding of a drug's biochemical properties, including potential liabilities in drug interactions